News

This approval marks a significant advancement for Viridian Therapeutics in the field of ophthalmic treatments. Lumvoa™ is a biologic targeting specific targets, and its approval offers a new treatment option for patients with thyroid eye disease. Thyroid eye disease is an autoimmune disorder associated with thyroid dysfunction, causing symptoms such as eye protrusion, double vision, impaired vision, and others, which severely impact patients' quality of life. The launch of this new drug is expected to address unmet medical needs in this disease area.The company stated it will promptly initiate the commercialization process for Lumvoa™ in the United States, ensuring that the drug can benefit patients in need as soon as possible. This approval is based on multiple clinical study data, which demonstrate the effectiveness and safety of the therapy in improving disease signs and symptoms.

Odaily reported that Base experienced a mainnet block production anomaly for the second time in two days. According to the official status page, the incident occurred at 15:33 UTC, with the team confirming the issue and resuming block production at 16:11. Base stated that node operators need to restart Base mainnet nodes to complete resynchronization. This incident displayed symptoms similar to the previous day’s outage. On Thursday, an abnormal block caused the Sequencer to be unable to continue constructing new blocks, resulting in the network being down for about two hours. Although user funds were not affected, withdrawal services were temporarily interrupted. The official announcement indicated that the latest failure also manifested as a chain halt, sharing key characteristics with the previous day’s incident. The network has now resumed operation.

According to Jinse Finance, the US Dollar Index fell by 0.07% on the 26th, closing at 101.357 at the end of the trading day in the foreign exchange market.